Amneal Pharmaceuticals, Inc
(NYSE:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics...

Website: http://www.amneal.com

Founded: 2002

Full Time Employees: 5,500

Sector: Healthcare

Industry: Drug Manufacturers-Specialty & Generic

Healthcare

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31

net revenue	722,519,000	814,319,000	784,513,000	724,508,000	695,420,000	730,518,000	702,468,000	701,780,000	659,191,000		599,046,000	557,540,000	609,759,000	545,557,000	559,355,000	497,633,000	536,896,000	528,593,000	535,075,000	493,105,000	510,034,000	519,294,000	464,662,000	498,533,000	397,328,000	378,283,000	404,642,000	446,120,000	497,528,000	476,487,000	413,787,000
cost of goods sold	402,406,000	517,129,000	510,539,000	438,255,000	439,529,000	467,645,000	432,910,000	451,833,000	421,131,000		379,025,000	379,354,000	389,046,000	350,653,000	353,724,000	323,062,000	348,490,000	329,394,000	322,577,000	301,543,000	342,962,000	353,345,000	319,666,000	313,578,000	273,373,000	267,717,000	296,381,000	309,743,000	304,120,000	276,382,000	235,492,000
gross profit	320,113,000	297,190,000	273,974,000	286,253,000	255,891,000	262,873,000	269,558,000	249,947,000	238,060,000		220,021,000	178,186,000	215,388,000	194,230,000	200,519,000	174,571,000	166,402,000	198,511,000	212,498,000	191,562,000	167,072,000	133,585,000	144,237,000	183,499,000	110,234,000	54,434,000	105,249,000	83,080,000	193,408,000	200,105,000	178,295,000
yoy	25.10%	13.05%	1.64%	14.53%	7.49%		22.51%	40.27%	10.53%		9.73%	2.07%	29.44%	-2.16%	-5.64%	-8.87%	-0.40%	48.60%	47.33%	4.39%	51.56%	145.41%	37.04%	120.87%	-43.00%	-72.80%	-40.97%
qoq	7.71%	8.47%	-4.29%	11.87%	-2.66%	-2.48%	7.85%	4.99%			23.48%	-17.27%	10.89%	-3.14%	14.86%	4.91%	-16.17%	-6.58%	10.93%	14.66%	25.07%	-7.39%	-21.40%	66.46%	102.51%	-48.28%	26.68%	-57.04%	-3.35%	12.23%
selling, general and administrative	138,860,000	146,458,000	137,815,000	124,266,000	118,288,000	128,687,000	118,692,000	116,462,000	112,595,000		105,570,000	102,096,000	102,158,000	100,071,000	98,806,000	98,665,000	97,224,000	91,397,000	86,157,000	90,726,000	84,687,000	83,120,000	80,944,000	77,976,000	74,084,000	63,797,000	67,281,000	84,436,000	74,236,000	78,075,000	53,003,000
research and development	38,383,000	34,819,000	63,352,000	47,964,000	40,040,000	54,265,000	61,097,000	36,054,000	39,298,000		37,799,000	38,690,000	41,907,000	50,235,000	50,748,000	52,798,000	51,874,000	48,927,000	52,864,000	48,182,000	53,460,000	44,519,000	45,572,000	36,379,000	48,050,000	38,125,000	48,016,000	53,858,000	56,647,000	42,999,000	50,335,000
intellectual property legal development expenses	1,542,000	1,411,000	2,437,000	2,017,000	1,767,000	1,852,000	1,967,000	1,042,000	984,000		820,000	1,644,000	1,362,000	1,411,000	821,000	764,000	1,142,000	1,627,000	1,365,000	3,582,000	3,701,000	2,134,000	3,550,000	1,270,000	4,975,000	2,586,000	2,511,000	4,166,000	3,237,000	4,401,000	4,047,000
acquisition costs	5,153,000
restructuring and other charges	650,000	2,470,000	143,000	1,024,000	571,000	493,000	172,000	220,000	1,470,000		82,000	510,000	109,000	581,000		731,000	1,069,000	425,000		363,000	-259,000	276,000	333,000	2,048,000	4,412,000	20,937,000	2,835,000	6,161,000
charges related to legal matters	694,000							699,000			2,017,000		20,094,000	285,000	251,877,000		6,000,000	19,000,000			1,465,000	60,000	1,300,000	4,500,000
other operating income	-6,941,000	-1,000	-117,000									-1,224,000	-1,465,000	-1,320,000	-1,175,000
operating income	141,772,000	112,033,000	70,344,000	111,372,000	100,347,000	75,793,000	88,809,000	95,470,000	-10,746,000		80,084,000	34,449,000	36,032,000	44,353,000	-198,618,000	23,305,000	11,175,000	28,515,000	67,119,000	45,907,000	20,178,000	2,435,000	10,751,000	57,791,000	-23,135,000	-112,274,000	-18,913,000	-94,360,000	23,280,000	74,555,000	-181,062,000
yoy	41.28%	47.81%	-20.79%	16.66%	-1033.81%		10.89%	177.13%	-129.82%		-140.32%	47.82%	222.43%	55.54%	-395.92%	-49.23%	-44.62%	1071.05%	524.30%	-20.56%	-187.22%	-102.17%	-156.84%	-161.25%	-199.38%	-250.59%	-89.55%
qoq	26.54%	59.26%	-36.84%	10.99%	32.40%	-14.66%	-6.98%	-988.42%			132.47%	-4.39%	-18.76%	-122.33%	-952.25%	108.55%	-60.81%	-57.52%	46.21%	127.51%	728.67%	-77.35%	-81.40%	-349.80%	-79.39%	493.63%	-79.96%	-505.33%	-68.77%	-141.18%
other income:
interest expense	-53,361,000	-56,237,000	-62,814,000	-65,101,000	-56,939,000	-61,662,000	-65,511,000	-65,719,000	-65,703,000		-50,857,000	-49,315,000	-47,028,000	-42,391,000	-35,623,000	-33,335,000	-33,957,000	-34,400,000	-34,083,000	-33,885,000	-34,535,000	-34,895,000	-36,669,000	-39,899,000	-38,829,000	-42,209,000	-43,886,000	-43,281,000	-42,880,000	-43,018,000	-36,622,000
foreign exchange gain	-7,800,000	-1,437,000	-3,431,000	8,256,000	4,247,000	-7,661,000	2,274,000	-262,000	-1,197,000		421,000	1,901,000				-2,013,000	-170,000	-29,000	-2,244,000	2,088,000	8,392,000	9,673,000	3,466,000				8,311,000	-5,464,000	2,817,000	-5,137,000	-25,946,000
loss on refinancing	-3,510,000		-31,365,000										-72,750		-291,000
decrease in tax receivable agreement liability	2,333,000	1,425,250	20,808,000
other income	742,000	13,165,000	1,235,000	1,604,000	518,000	2,172,000	1,178,000	4,360,000	4,072,000		12,000	3,539,000	2,772,000	5,709,000	7,230,000	2,122,000	6,633,000	3,871,000	4,032,000	794,000	488,000	898,000	571,000	633,000	-237,000	446,000	149,000	1,107,000	2,123,000	-1,014,000	791,000
total other expense	-61,596,000	-56,798,000	-75,567,000		-62,861,000	-91,112,000	-73,386,000	-75,065,000	-64,776,000		-50,424,000	-43,875,000	-43,687,000	-42,173,000	-34,113,000	-33,226,000	-23,464,000	-30,558,000	-32,295,000	-31,003,000			-32,509,000	-44,447,000			-37,314,000	-38,820,000	-38,086,000	-51,981,000	-81,444,000
income before income taxes	80,176,000	55,235,000	-5,223,000	51,711,000	37,486,000	-15,319,000	15,423,000	20,405,000	-75,522,000		29,660,000	-9,426,000	-7,655,000	2,180,000	-232,731,000	-9,921,000	-16,319,000	-2,043,000	34,824,000	14,904,000	-5,477,000	-21,889,000	-21,758,000	13,344,000	-57,111,000	26,276,000	-56,227,000	-133,180,000	-14,806,000	22,574,000	-262,506,000
provision for income taxes	2,176,000	5,662,000	-23,355,000		12,868,000	5,423,000	3,666,000	3,618,000	6,156,000		-23,000	668,000	-1,797,000	4,570,000	7,350,000	-3,461,000	4,140,000	4,049,000	2,648,000	359,000	1,485,000	144,000	2,186,000		7,792,000	389,668,000		-8,428,000	5,524,000	5,109,000	-12,416,000
net income	78,000,000	49,573,000	18,132,000	35,610,000	24,618,000	-20,742,000	11,757,000	16,787,000	-81,678,000		29,683,000	-10,094,000	-5,858,000	-2,390,000	-240,081,000	-6,460,000	-20,459,000	-6,092,000	32,176,000	14,545,000	-6,962,000	-22,033,000	-23,944,000	121,517,000	-64,903,000	-363,392,000	-50,526,000	-124,752,000	-20,330,000	17,465,000	-250,090,000
yoy	216.84%	-339.00%	54.22%	112.13%	-130.14%		-60.39%	-266.31%	1294.30%		-112.36%	56.25%	-71.37%	-60.77%	-846.15%	-144.41%	193.87%	-72.35%	-234.38%	-88.03%	-89.27%	-93.94%	-52.61%	-197.41%	219.25%	-2180.69%	-79.80%	NaN%
qoq	57.34%	173.40%	-49.08%	44.65%	-218.69%	-276.42%	-29.96%	-120.55%			-394.07%	72.31%	145.10%	-99.00%	3616.42%	-68.42%	235.83%	-118.93%	121.22%	-308.92%	-68.40%	-7.98%	-119.70%	-287.23%	-82.14%	619.22%	-59.50%	513.64%	-216.40%	-106.98%	NaN%
less: net income attributable to non-controlling interests	-15,744,000	-14,497,000	-15,763,000	-13,193,000	-12,423,000	-8,167,750	-11,913,000	-10,793,000												-7,839,000
net income attributable to amneal pharmaceuticals, inc.	62,256,000	35,076,000	2,369,000	22,417,000	12,195,000	-21,451,250	-156,000	5,994,000			11,917,000		-4,333,000	-2,689,000	-120,808,000	-2,156,000	-6,377,000	-4,237,000	14,532,000	6,706,000	-3,037,000	-8,975,000	-11,996,000	115,067,000	-82,447,250	-265,006,000			-3,038,000	6,952,000
net income per share
basic	0.2	0.11	0.01	0.07	0.04	-0.07		0.02			0.08		-0.03	-0.02	-0.8	-0.01	0.028	-0.03	0.1	0.05
diluted	0.19	0.11	0.01	0.07	0.04	-0.07		0.02			0.08		-0.03	-0.02	-0.8	-0.01	0.028	-0.03	0.1	0.04
weighted-average common shares outstanding:
basic	316,023	313,367	314,168	313,739	311,054		309,647	309,117		176,136	153,738		150,944	151,393	150,993	149,892		149,290	148,996	148,013
diluted	328,933	324,805	324,754	322,363	323,961		309,647	318,957		176,136	154,887		150,944	151,393	150,993	149,892		149,290	151,986	151,220
(credit) charges related to legal matters				-390,000		23,727,250	-149,000
increase in tax receivable agreement liability				-4,420,000	-10,687,000	-23,961,000	-11,327,000	-13,444,000	-1,948,000
total other income				-59,661,000																	-25,655,000	-24,324,000			-33,976,000	138,550,000
benefit from income taxes				16,101,000																				-108,173,000			-5,701,000
other operating expense					-5,122,000						13,000
change in fair value of contingent consideration							-1,030,000		100,000		-6,364,000	2,457,000	2,226,000	-1,425,000	-270,000	200,000	-100,000	300,000
charges (credit) related to legal matters									94,359,000
less: net loss attributable to non-controlling interests									-9,965,000		-17,766,000	3,151,000	1,525,000	-299,000	119,273,000	4,742,000	14,082,000	1,855,000	-17,644,000		3,925,000	13,058,000	11,948,000	-6,450,000	32,775,000	98,386,000	33,624,000	76,871,000	11,562,000	-10,577,000	31,885,000
net loss attributable to amneal pharmaceuticals, inc.									-91,643,000			-6,943,000															-16,902,000	-47,881,000			-19,104,000
net income per share
basic and diluted									-0.3			-0.05
weighted-average common shares outstanding:
basic and diluted						308,978			307,279			152,109																				1,000
acquisition, transaction-related and integration expenses													-5,000	39,000	241,000	434,000	836,000	134,000	4,283,000	2,802,000	3,585,000	1,041,000	1,787,000	2,575,000	3,706,000	3,131,000	3,519,000	6,032,000	4,945,000	2,231,000	207,507,000
insurance recoveries for property losses and associated expenses															-1,911,000
net income attributable to amneal pharmaceuticals, inc. before accretion of redeemable non-controlling interest											11,917,000		-4,333,000	-2,689,000	-120,808,000	-1,718,000									-82,447,250	-265,006,000			-2,744,000	6,888,000
accretion of redeemable non-controlling interest																-438,000														64,000	-1,240,000
credit related to legal matters												-436,000				-2,326,000
net loss attributable to amneal pharmaceuticals, inc. before accretion of redeemable non-controlling interest												-6,943,000															-16,902,000				-17,864,000
cost of goods sold impairment charges													5,325,000	674,000	5,112,000		22,004,000	688,000				32,364,000	759,000	1,456,000	13,721,000	56,132,000	3,012,000	53,297,000
in-process research and development impairment charges																			710,000		1,720,000			960,000	450,000	23,382,000		22,787,000
charges (insurance recoveries) for property losses and associated expenses													-477,750
foreign exchange loss													-3,233,250	-5,491,000	-5,429,000									-5,181,000	-2,421,000	-12,531,000
property losses and associated expenses																	-2,818,000	8,186,000
gain on sale of international businesses																							123,000		328,000		-1,888,000
gain from reduction of tax receivable agreement liability																									40,000	192,844,000
net income per share
class a and class b-1 basic																					-0.02	-0.06	-0.08	0.78	-0.64	-2.03			-0.025	0.05
class a and class b-1 diluted																					-0.02	-0.06	-0.08	0.78	-0.64	-2.03			-0.025	0.05
weighted-average common shares outstanding:
gain on sale of international business																												8,818,000
charges (gains) related to legal matters																									-2,308,000	14,750,000
loss on extinguishment of debt																															-19,667,000
less: net loss attributable to amneal pharmaceuticals llc pre- combination
legal settlement gains
less: net loss attributable to amneal pharmaceuticals llc pre-combination																															200,341,000
class a and class b-1 basic and diluted																											-0.13	-0.37			-0.15
less: net income attributable to amneal pharmaceuticals llc pre-combination
legal settlement gain
restructuring expenses																													10,577,250	-2,156,000	44,465,000
loss on sale of certain international businesses																													-146,000	-2,812,000
total operating expenses
earnings per share:
basic and diluted
weighted-average shares outstanding:
basic and diluted						308,978			307,279			152,109																				1,000

Balance Sheets:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31

assets
current assets:
cash and cash equivalents	201,249,000	71,544,000	59,187,000	110,552,000	74,006,000	43,769,000	46,520,000	91,542,000	109,284,000	144,674,000	25,976,000	87,335,000	91,979,000	210,477,000	247,790,000	302,655,000	278,306,000	452,097,000	341,378,000	281,278,000	266,143,000	405,238,000	151,197,000	212,738,000	54,893,000	63,946,000	213,394,000	165,192,000	61,521,000
restricted cash	34,727,000	9,642,000	6,583,000	7,868,000	4,339,000	5,853,000	5,097,000	7,565,000	5,298,000	6,395,000	9,251,000	8,556,000	6,203,000	6,068,000	8,949,000	7,964,000	4,847,000	3,717,000	5,743,000	2,372,000	2,129,000	1,687,000	1,625,000	4,320,000	2,129,000	2,797,000	5,385,000	7,001,000	7,069,000
trade accounts receivable	885,199,000	807,637,000	754,236,000	775,731,000	748,055,000	769,871,000	668,955,000	613,732,000	674,736,000	545,760,000	741,791,000	628,737,000	688,849,000	538,309,000	662,583,000	627,954,000	652,015,000	530,600,000	638,895,000	707,103,000	582,734,000	722,682,000	604,390,000	518,109,000	634,666,000	640,212,000	481,495,000	641,029,000	626,491,000
inventories	614,500,000	608,973,000	601,433,000	612,454,000	596,359,000	575,624,000	570,653,000	581,384,000	550,558,000	529,042,000	530,735,000	543,858,000	533,028,000	512,241,000	489,389,000	520,245,000	523,385,000	497,008,000	490,649,000	475,760,000	443,956,000	437,959,000	381,067,000	401,827,000	414,627,000	448,294,000	457,219,000	490,768,000	512,479,000
prepaid expenses and other current assets	101,511,000	85,304,000	88,524,000	80,717,000	81,956,000	81,596,000	87,298,000	82,685,000	81,764,000	81,424,000	103,565,000	149,650,000	232,204,000	121,408,000	110,218,000	110,212,000	103,798,000	75,137,000	73,467,000	76,264,000	184,748,000	204,409,000	70,164,000	66,699,000	77,062,000	111,563,000	128,321,000	126,386,000	139,596,000
related party receivables	1,292,000	1,592,000	487,000	484,000	8,579,000	8,767,000	1,521,000	955,000	149,000	30,000	500,000	1,696,000	1,338,000	1,175,000	1,179,000	1,307,000	1,124,000	1,102,000	1,407,000	942,000	1,164,000	1,725,000	1,767,000	2,138,000	2,470,000	1,156,000	830,000	925,000	738,000
total current assets	1,838,478,000	1,584,692,000	1,510,450,000	1,587,806,000	1,513,294,000	1,485,480,000	1,380,044,000	1,377,863,000	1,421,789,000	1,307,325,000	1,411,818,000	1,419,832,000	1,553,601,000	1,389,678,000	1,520,108,000	1,570,337,000	1,563,475,000	1,559,661,000	1,551,539,000	1,543,719,000	1,480,874,000	1,773,700,000	1,210,210,000	1,205,831,000	1,185,847,000	1,267,968,000	1,286,644,000	1,431,301,000	1,347,894,000
property, plant and equipment	434,991,000	440,327,000	427,231,000	424,908,000	431,020,000	425,380,000	439,815,000	447,574,000	459,108,000	462,606,000	469,815,000	470,150,000	483,625,000	500,911,000	514,158,000	459,651,000	468,415,000	471,165,000	477,754,000	462,438,000	460,528,000	467,559,000	477,997,000	490,712,000	508,086,000	514,414,000	544,146,000	567,498,000	569,328,000
goodwill	595,945,000	597,406,000	597,497,000	597,436,000	598,324,000	598,533,000	598,549,000	598,629,000	599,206,000	599,156,000	598,853,000	599,504,000	600,974,000	602,893,000	593,017,000	566,406,000	549,091,000	522,758,000	522,814,000	522,690,000	527,475,000	514,733,000	419,504,000	419,671,000	420,017,000	421,640,000	426,226,000	410,616,000	386,475,000
intangible assets	587,938,000	649,547,000	689,136,000	732,377,000	780,189,000	819,944,000	859,272,000	890,423,000	1,015,376,000	1,055,319,000	1,096,093,000	1,159,005,000	1,204,224,000	1,209,818,000	1,166,922,000	1,232,727,000	1,293,325,000	1,262,954,000	1,304,626,000	1,349,113,000	1,423,826,000	1,475,161,000	1,382,753,000	1,435,801,000	1,553,330,000	1,591,158,000	1,654,969,000	1,733,020,000	1,788,533,000
operating lease right-of-use assets	31,769,000	33,241,000	29,103,000	31,388,000	32,872,000	33,284,000	32,970,000	30,329,000	34,031,000	36,127,000	38,211,000	34,252,000	36,490,000	37,675,000	39,899,000	38,993,000	41,065,000	32,396,000	33,947,000	43,643,000	49,159,000	50,943,000	53,344,000	56,455,000	59,900,000	63,238,000
operating lease right-of-use assets - related party	16,875,000	17,658,000	10,447,000	10,964,000	11,473,000	11,974,000	12,468,000	12,954,000	16,566,000	17,244,000	17,910,000	18,566,000	19,212,000	19,846,000	20,471,000	21,085,000	21,689,000	24,110,000	24,792,000	25,463,000	26,183,000	21,616,000	16,528,000	14,930,000	17,031,000	17,565,000
financing lease right-of-use assets	54,420,000	55,068,000	55,967,000	56,433,000	57,532,000	58,299,000	59,532,000	59,280,000	61,570,000	62,400,000	63,424,000	64,468,000	63,443,000	64,204,000	64,475,000	65,682,000	66,777,000	67,465,000
other assets	39,458,000	44,849,000	45,418,000	60,133,000	36,274,000	77,028,000	73,747,000	55,517,000	93,240,000	86,428,000	103,217,000	108,262,000	79,836,000	63,943,000	20,614,000	19,528,000	19,216,000	19,561,000	31,885,000	31,142,000	28,731,000	26,456,000	44,270,000	18,607,000	63,459,000	62,422,000	67,592,000	73,642,000	78,653,000
total assets	3,599,874,000	3,422,788,000	3,365,249,000	3,501,445,000	3,460,978,000	3,509,922,000	3,456,397,000	3,472,569,000	3,700,886,000	3,626,605,000	3,799,341,000	3,874,039,000	4,041,405,000	3,888,968,000	3,939,664,000	3,974,409,000	4,023,053,000	3,960,070,000	4,006,033,000	4,037,536,000	4,056,756,000	4,390,800,000	3,665,890,000	3,703,943,000	4,262,139,000	4,384,586,000	4,352,736,000	4,582,048,000	4,544,588,000
liabilities and stockholders’ deficiency
current liabilities:
accounts payable and accrued expenses	731,825,000	666,817,000	628,572,000	735,450,000	671,085,000	619,194,000	558,518,000	534,662,000	512,719,000	467,421,000	538,199,000	531,462,000	561,692,000	539,734,000	583,345,000	589,412,000	596,227,000	574,322,000	613,661,000	613,619,000	599,489,000	606,925,000	507,483,000	495,857,000	505,143,000	558,750,000	514,440,000	513,122,000	555,634,000
current portion of liabilities for legal matters	40,598,000	41,515,000	43,503,000	31,755,000	30,181,000	30,740,000	30,130,000	76,988,000	77,011,000	76,317,000	107,483,000	176,094,000	275,338,000
revolving credit facility		290,000,000	290,000,000	100,000,000	140,000,000	179,000,000	179,000,000	179,000,000		100,000,000	60,000,000	60,000,000	85,000,000									300,000,000
current portion of long-term debt	7,202,000	31,175,000	31,790,000	224,213,000	224,692,000	225,156,000	33,660,000	34,125,000	30,405,000	29,965,000	29,961,000	29,940,000	29,920,000	30,523,000	30,614,000	30,471,000	30,461,000	29,817,000	44,228,000	29,776,000	29,756,000	29,736,000	21,479,000	21,468,000	21,445,000	21,445,000	21,449,000		21,427,000
current portion of operating lease liabilities	7,985,000	8,223,000	8,986,000	9,435,000	9,702,000	9,669,000	9,508,000	9,207,000	9,861,000	9,017,000	8,321,000	10,266,000	10,096,000	9,901,000	9,686,000	9,180,000	8,237,000	6,637,000	6,474,000	11,527,000	12,512,000	12,125,000	11,874,000	13,467,000	13,313,000	13,173,000
current portion of operating lease liabilities - related party	2,826,000	2,701,000	3,449,000	3,396,000	3,327,000	3,259,000	3,192,000	2,825,000	2,992,000	2,930,000	2,869,000
current portion of financing lease liabilities	3,458,000	3,307,000	3,319,000	3,211,000	3,300,000	3,199,000	3,305,000	2,467,000	3,219,000	3,309,000	3,488,000	3,557,000	3,318,000	3,233,000	3,101,000	3,218,000	2,806,000	3,020,000
related party payables - short term	68,212,000	63,396,000	66,205,000	22,311,000	12,922,000	12,773,000	17,075,000	7,321,000	21,143,000	14,750,000	2,479,000	3,867,000	24,904,000	15,960,000	47,861,000				7,561,000
total current liabilities	862,106,000	1,107,134,000	1,075,824,000	1,129,771,000	1,095,209,000	1,114,353,000	834,388,000	846,595,000	777,350,000	703,709,000	752,800,000	817,995,000	993,064,000	602,043,000	677,243,000	667,335,000	672,862,000	636,779,000	676,902,000	667,886,000	655,019,000	965,065,000	550,406,000	534,910,000	546,159,000	599,530,000	553,850,000	749,271,000	669,736,000
long-term debt	2,566,500,000	2,146,403,000	2,153,979,000	2,161,790,000	2,169,607,000	2,177,578,000	2,377,707,000	2,386,004,000	2,549,177,000	2,561,724,000	2,591,981,000	2,607,217,000	2,622,447,000	2,672,661,000	2,680,053,000	2,687,668,000	2,720,117,000	2,728,212,000	2,735,264,000	2,757,139,000	2,764,578,000	2,772,029,000	2,609,046,000	2,614,412,000	2,619,788,000	2,625,152,000	2,630,598,000		2,641,305,000
operating lease liabilities	26,405,000	27,623,000	22,854,000	24,814,000	26,210,000	26,782,000	26,786,000	24,095,000	28,296,000	30,782,000	32,126,000	26,366,000	28,904,000	30,378,000	32,894,000	32,562,000	34,723,000	28,435,000	30,182,000	34,849,000	38,591,000	40,615,000	43,135,000	44,375,000	47,836,000	51,200,000
operating lease liabilities - related party	15,676,000	16,441,000	8,520,000	9,391,000	10,265,000	11,126,000	11,969,000	12,787,000	14,388,000	15,163,000	15,914,000	16,653,000	17,380,000	18,093,000	18,783,000	19,462,000	20,131,000	22,308,000	23,049,000	23,777,000	24,478,000	19,874,000	15,469,000	14,271,000	14,862,000	15,445,000
financing lease liabilities	55,672,000	56,020,000	56,604,000	56,889,000	57,558,000	58,007,000	58,809,000	58,566,000	59,836,000	60,241,000	60,769,000	61,311,000	60,011,000	60,286,000	60,251,000	60,966,000	61,643,000	61,871,000
related party payables - long term	8,587,000	15,607,000	10,687,000		26,186,000	16,146,000	11,394,000		9,123,000	11,207,000		10,296,000	10,654,000	10,371,000
liabilities for legal matters - long term	74,477,000	74,477,000	72,979,000	85,479,000	85,479,000	85,479,000	85,479,000
other long-term liabilities	32,626,000	25,814,000	23,191,000	26,949,000	24,144,000	24,518,000	24,579,000	29,995,000	39,282,000	41,456,000	87,468,000	78,258,000	79,213,000	32,866,000	38,903,000	60,795,000	63,255,000	63,789,000	85,683,000	96,188,000	93,772,000	80,846,000	39,583,000				38,780,000	44,769,000	45,667,000
total long-term liabilities	2,779,943,000	2,362,385,000	2,348,814,000	2,416,212,000	2,399,449,000	2,399,636,000	2,638,616,000	2,564,670,000	2,740,662,000	2,760,701,000	2,837,613,000	2,839,380,000	2,857,465,000	2,863,098,000	2,878,541,000	2,908,648,000	2,945,807,000	2,943,504,000	2,972,395,000	3,009,522,000	3,018,341,000	3,009,714,000	2,768,696,000	2,773,309,000	2,966,628,000	2,985,275,000	2,902,523,000	2,917,458,000	2,923,508,000
commitments and contingencies
redeemable non-controlling interests	67,780,000	65,802,000	72,611,000	64,974,000	59,887,000	53,422,000	47,022,000	41,293,000	32,106,000	27,527,000	24,949,000	22,375,000	17,885,000	16,420,000	16,907,000	15,260,000	14,112,000	13,079,000		11,932,000	12,380,000	12,563,000
stockholders’ deficiency
preferred stock, 0.01 par value...
class a common stock, 0.01 par value...	3,143,000	3,140,000	3,134,000	3,099,000	3,098,000	3,095,000	3,086,000	3,066,000	1,540,000	1,532,000	1,514,000	1,513,000	1,510,000	1,506,000	1,492,000	1,492,000	1,490,000	1,485,000	1,475,000	1,475,000	1,474,000	1,472,000	1,470,000	1,340,000	1,281,000	1,156,000	1,151,000	1,150,000	1,149,000
class b common stock, 0.01 par value...									1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,522,000	1,651,000	1,710,000	1,710,000	1,713,000	1,713,000	1,713,000
additional paid-in capital	563,363,000	554,623,000	545,806,000	560,206,000	553,233,000	545,701,000	538,720,000	539,240,000	708,233,000	700,722,000	691,629,000	683,745,000	675,588,000	666,799,000	658,350,000	650,539,000	642,657,000	634,484,000	628,413,000	623,133,000	617,504,000	611,600,000	606,966,000	565,641,000	544,161,000	537,159,000	530,438,000	520,160,000	517,122,000
stockholders' accumulated deficit	-570,081,000	-572,450,000	-594,867,000	-607,062,000	-575,981,000	-575,825,000	-581,819,000	-490,176,000	-401,209,000	-413,126,000	-406,183,000	-401,850,000	-399,161,000	-278,353,000		-269,820,000	-265,583,000	-280,115,000	-286,821,000	-283,784,000	-274,809,000	-262,813,000	-377,880,000	-345,752,000	-80,746,000	-63,844,000	-20,920,000	-12,152,000	-19,104,000
accumulated other comprehensive loss	-105,883,000	-97,431,000	-85,740,000	-65,510,000	-73,782,000	-30,436,000	-23,711,000							-349,000	-24,827,000	-33,227,000	-33,979,000	-34,361,000	-41,318,000	-41,306,000	-39,696,000	-33,405,000	-68,000	-4,879,000	-6,750,000	-4,099,000	-7,755,000
total amneal pharmaceuticals, inc. stockholders’ deficiency	-109,458,000	-112,118,000	-131,667,000
non-controlling interests	-497,000	-415,000	-333,000	-245,000	-135,000	-24,000	95,000	230,000	-167,401,000	-159,746,000	-114,442,000	-103,180,000	-107,336,000	16,282,000	6,633,000	32,660,000	44,165,000	43,693,000	41,661,000	47,156,000	65,021,000	85,082,000	114,778,000	177,723,000	289,696,000	327,576,000	391,613,000	414,214,000	444,985,000
total stockholders' deficiency	-109,955,000	-112,533,000	-132,000,000
total liabilities and stockholders’ deficiency	3,599,874,000	3,422,788,000	3,365,249,000
cash flows from operating activities:
net income	78,360,000	60,228,000	24,618,000		-53,134,000	-64,891,000	-81,678,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	174,345,000	120,272,000	60,159,000		170,061,000	111,100,000	55,528,000
unrealized foreign currency gain	-8,606,000					2,080,000	1,511,000
amortization of debt issuance costs and discount	18,716,000	13,686,000	6,811,000		2,662,000	1,221,000	288,000
reclassification of cash flow hedge	-1,713,000	-5,876,000	-6,444,000
loss on refinancing	31,365,000
intangible asset impairment charges	22,784,000				920,000	920,000	920,000
stock-based compensation	23,751,000	15,532,000	7,258,000		20,558,000	13,446,000	6,722,000
inventory provision	59,326,000	38,432,000	23,669,000		63,611,000	41,493,000	22,923,000
other operating charges and credits	3,575,000	2,254,000	1,313,000		-50,000	-1,531,000	1,250,000
changes in assets and liabilities:
prepaid expenses, other current assets and other assets	-20,173,000	-10,015,000	-513,000		-2,082,000	-8,418,000	-11,708,000
accounts payable, accrued expenses and other liabilities	2,744,000	-67,004,000	-112,626,000		168,879,000	122,026,000	62,174,000
related party payables	3,107,000	5,293,000	-1,124,000		20,339,000	9,619,000	5,495,000																5,969,000	765,000	2,965,000	2,928,000	17,695,000	36,329,000
net cash from operating activities	209,677,000	91,227,000	7,408,000		177,021,000	35,247,000	-4,410,000
cash flows from investing activities:
purchases of property, plant and equipment	-48,290,000	-35,992,000	-13,162,000		-36,769,000	-19,824,000	-9,198,000
acquisition of intangible assets	-12,514,000	-5,100,000	-4,200,000		-14,050,000	-10,450,000	-9,700,000
deposits for future acquisition of property, plant and equipment	-7,384,000	-4,632,000	-960,000		-1,107,000	-940,000	-862,000
proceeds from sale of property, plant and equipment	1,379,000	1,379,000	524,000
proceeds from sale of subsidiary					4,989,000	4,989,000
net cash from investing activities	-66,809,000	-44,345,000	-17,798,000		-46,937,000	-26,225,000	-19,760,000
cash flows from financing activities:
proceeds from issuance of debt	2,694,750,000
payments of principal on debt, revolving credit facilities, financing leases and other	-2,805,384,000	-251,076,000	-235,528,000		-133,383,000	-78,877,000	-63,377,000
payments of deferred financing and refinancing costs	-74,973,000	-1,745,000
borrowings on revolving credit facilities	218,000,000	218,000,000	218,000,000		48,000,000	48,000,000	48,000,000
proceeds from exercise of stock options	1,407,000	754,000	69,000		1,003,000	386,000	28,000
employee payroll tax withholding on restricted stock unit and performance stock unit vesting	-21,957,000	-21,828,000	-21,639,000
tax and other distributions to non-controlling interests	-38,825,000	-24,958,000
payment of principal on notes payable - related party					-44,200,000	-11,496,000
proceeds from alliance party	5,572,000
net cash from financing activities	-21,410,000	-80,853,000	-39,166,000		-150,587,000	-58,241,000	-23,155,000
effect of foreign exchange rate on cash	-1,471,000	-777,000	-470,000		-259,000	-266,000	-165,000
net increase in cash, cash equivalents, and restricted cash	119,987,000				-20,762,000	-49,485,000	-47,490,000
cash, cash equivalents, and restricted cash - beginning of period	118,420,000	118,420,000	118,420,000		99,107,000	99,107,000	99,107,000
cash, cash equivalents, and restricted cash - end of period	238,407,000	83,672,000	68,394,000		78,345,000	49,622,000	51,617,000
cash and cash equivalents - end of period	201,249,000	71,544,000	59,187,000		74,006,000	43,769,000	46,520,000
restricted cash - end of period	34,727,000	9,642,000	6,583,000		4,339,000	5,853,000	5,097,000
long-term restricted cash included in other assets - end of period	2,431,000	2,486,000	2,624,000
unrealized foreign currency (gain) loss		-11,813,000	-3,596,000		-754,000
net decrease in cash, cash equivalents, and restricted cash		-34,748,000	-50,026,000
tax distributions to non-controlling interests			-68,000		-14,442,000	-8,883,000	-594,000
liabilities and stockholders’ (deficiency) equity
note payable - related party							41,893,000	41,447,000	40,560,000	40,128,000	39,706,000	39,279,000	38,856,000	38,443,000	38,038,000	37,629,000	37,224,000	36,828,000	36,440,000	36,048,000	35,661,000	35,281,000
related party payable - long term				50,900,000				11,776,000			9,649,000				9,619,000	9,566,000	8,714,000	2,061,000	1,584,000	1,031,000	479,000
stockholders’ (deficiency) equity:
total amneal pharmaceuticals, inc. stockholders' (deficiency) equity				-109,267,000	-93,432,000	-57,465,000	-63,724,000
total stockholders' (deficiency) equity				-109,512,000	-93,567,000	-57,489,000	-63,629,000
total liabilities and stockholders' (deficiency) equity				3,501,445,000	3,460,978,000	3,509,922,000	3,456,397,000
balance at december 31, 2023				306,565,000
foreign currency translation adjustments
exercise of stock options				397,000
restricted stock unit vesting, net of shares withheld to cover payroll taxes				2,919,000
unrealized loss on cash flow hedge, net of tax of 0
tax distributions
reclassification of cash flow hedge to earnings, net of tax of 0
balance at december 31, 2024				309,881,000
liabilities and stockholders' (deficiency) equity
stockholders' (deficiency) equity
change in fair value of contingent consideration					-930,000	100,000	100,000
employee payroll tax withholding on restricted stock unit vesting					-7,565,000	-7,371,000	-7,212,000
current portion of notes payable - related party						31,363,000
liabilities and stockholders’ equity
stockholders’ equity:
accumulated other comprehensive income								-32,349,000	8,083,000	3,764,000	9,939,000	12,539,000	868,000
total amneal pharmaceuticals, inc. stockholders' equity								19,781,000	318,169,000	294,414,000	298,421,000	297,469,000	280,327,000	391,125,000		350,506,000	346,107,000	323,015,000	303,271,000	301,040,000	305,995,000	318,376,000	232,010,000	218,001,000	459,656,000	472,205,000	504,750,000
total stockholders' equity								20,011,000	150,768,000	134,668,000	183,979,000	194,289,000	172,991,000	407,407,000		383,166,000	390,272,000	366,708,000	344,932,000	348,196,000	371,016,000	403,458,000	346,788,000	395,724,000	749,352,000	799,781,000	896,363,000
total liabilities and stockholders' equity								3,472,569,000	3,700,886,000	3,626,605,000	3,799,341,000	3,874,039,000	4,041,405,000	3,888,968,000		3,974,409,000	4,023,053,000	3,960,070,000	4,006,033,000	4,037,536,000	4,056,756,000	4,390,800,000	3,665,890,000	3,703,943,000	4,262,139,000	4,384,586,000	4,352,736,000
liabilities and stockholders' equity
revolving credit facilities									120,000,000
stockholders' equity
current portion of operating and financing lease liabilities - related party												2,809,000	2,796,000	2,692,000	2,636,000	2,580,000	2,201,000	2,883,000	3,978,000	3,895,000	3,807,000	4,084,000	3,601,000	3,353,000	3,293,000	3,234,000
financing lease right-of-use assets - related party																			58,676,000	59,328,000	59,980,000	60,632,000	61,284,000	61,936,000	62,588,000	63,240,000
current portion of note payable - related party																			1,000,000	1,000,000	1,000,000
financing lease liabilities - related party																			60,193,000	60,490,000	60,782,000	61,069,000	61,463,000	61,719,000	61,990,000	62,256,000
stockholders’ accumulated deficit															-276,197,000
total amneal pharmaceuticals, inc. stockholders’ equity															360,340,000
total stockholders’ equity															366,973,000
total liabilities and stockholders’ equity															3,939,664,000
related party payable - short term																32,474,000	32,930,000	20,100,000		8,069,000	8,455,000
redeemable non-controlling interest																			11,804,000										11,858,000
stockholders' equity:
current portion of note payable- related party																						1,000,000
related party payable																						11,195,000
deferred tax asset																									391,881,000	382,941,000	373,159,000	365,971,000	373,705,000
current portion of financing obligation - related party																											266,000
financing obligations - related party																											39,083,000
deferred income taxes																											1,178,000	1,761,000	2,491,000
liabilities under tax receivable agreement																									193,499,000	193,499,000	192,884,000	195,820,000	194,825,000
class b-1 common stock, 0.01 par value...																										123,000	123,000	123,000	123,000
financing obligation - related party
other liabilities																								38,532,000	28,653,000	37,723,000
members' equity, 189,000 units authorized, issued and outstanding at december 31, 2017
members' accumulated deficit
liabilities and stockholders' equity / members' deficit
note payable and accrued interest-related party																												78,126,000
current portion of long-term debt and financing obligations																												121,694,000
long-term debt and financing obligations																												2,675,108,000
related party payable- long term
stockholders' equity / members' deficit:
stockholders' accumulated other comprehensive loss																												-9,889,000	-6,502,000
total amneal pharmaceuticals, inc. stockholders' equity/ members' deficit																												501,105,000	494,501,000
total stockholders' equity/ members' deficit																												915,319,000	939,486,000
total liabilities and stockholders' equity/ members’ deficit																												4,582,048,000	4,544,588,000
note payable-related party																													77,549,000
current portion of financing obligations																													251,000
related-party payables																													14,875,000
long-term portion of financing obligations																													39,220,000
related-party payable- long term
total liabilities
stockholder’s equity:
common stock, 0.01 par value...																														10	10
stockholder receivable																														-10	-10
total stockholder’s equity
total liabilities and stockholder’s equity
net revenue
total operating expenses
benefit from income taxes
earnings per share:
basic and diluted
weighted-average shares outstanding:

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31

cash flows from operating activities:
net income	78,000,000	49,573,000	18,132,000	35,610,000	24,618,000		11,757,000					-5,858,000	-2,390,000	-240,081,000	-6,460,000	-20,459,000	-6,092,000	32,176,000	14,545,000	-6,962,000	-22,033,000	-23,944,000	121,517,000				-124,752,000	-20,330,000	17,465,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	43,191,000	49,227,000	54,073,000	60,113,000	60,159,000	66,130,000	58,961,000	55,572,000	55,528,000	57,111,000	58,150,000	61,056,000	61,608,000	59,696,000	57,815,000	61,183,000	60,186,000	56,488,000	55,549,000	59,873,000	59,359,000	58,072,000	58,083,000	54,303,000	53,358,000	50,706,000	48,868,000	47,493,000	43,013,000
unrealized foreign currency loss	8,215,000				-3,596,000	7,945,000	-2,834,000	569,000	1,511,000	426,000	-1,987,000	2,297,000	4,879,000	4,874,000	3,140,000	269,000	-218,000	2,094,000	-1,970,000	-8,949,000	-9,030,000	-4,263,000	5,514,000	-3,210,000	14,247,000	-10,185,000	6,490,000	-2,978,000	4,528,000
amortization of debt issuance costs and discount	3,890,000	3,715,000	5,030,000	6,875,000	6,811,000	26,435,000	1,441,000	933,000	288,000	2,465,000	2,058,000	2,106,000	2,101,000	2,193,000	2,195,000		2,400,000	2,290,000	2,183,000		2,235,000	2,210,000	2,004,000
reclassification of cash flow hedge	2,878,000	2,942,000	4,163,000	568,000	-6,444,000
loss on refinancing	3,510,000	0											0
stock-based compensation	8,816,000	8,202,000	8,219,000	8,274,000	7,258,000	7,210,000	7,112,000	6,724,000	6,722,000	6,561,000	7,596,000	7,831,000	7,689,000	8,262,000	8,065,000	7,742,000	7,708,000	7,632,000	5,330,000		5,415,000	5,663,000	4,539,000
inventory provision	13,353,000	26,636,000	20,894,000	14,763,000	23,669,000	32,947,000	22,118,000	18,570,000	22,923,000	16,602,000	25,204,000	22,212,000	11,136,000	14,170,000	3,578,000	15,370,000	13,485,000	9,784,000	16,021,000	19,038,000	21,490,000	19,508,000	15,200,000	14,401,000	17,434,000	34,760,000	15,650,000	23,784,000	3,329,000
other operating charges and credits	1,486,000	1,157,000	1,321,000	941,000	1,313,000	2,503,000	1,481,000	-2,781,000	1,250,000	1,317,000	2,047,000	1,751,000	3,628,000	2,294,000	1,155,000	1,668,000	1,201,000	1,333,000	1,431,000	5,570,000	2,092,000	2,890,000	1,266,000	1,364,000	2,790,000	2,046,000	1,109,000	89,000
changes in assets and liabilities:
trade accounts receivable	44,013,000	-10,338,000	-77,613,000	-53,763,000	21,148,000	-28,606,000	21,812,000	-100,670,000	-55,173,000	-128,994,000	195,970,000	-113,287,000	60,131,000	-150,829,000	124,268,000	-34,515,000	24,061,000	-121,552,000	108,385,000	67,535,000	-126,517,000	136,662,000	-60,893,000	-86,269,000	116,497,000	2,058,000	-165,012,000	163,795,000	-14,660,000
inventories	-54,959,000	-20,180,000	-30,807,000	-22,776,000	-13,263,000	-51,985,000	-43,098,000	-23,247,000	-12,200,000	-38,018,000	-22,508,000	-11,070,000	-25,931,000	-39,846,000	-25,549,000	16,628,000	-11,063,000	-34,297,000	-20,283,000	-33,060,000	-47,540,000	-30,404,000	-2,778,000	5,513,000	-6,248,000	-5,478,000	-14,180,000	10,833,000	17,947,000
prepaid expenses, other current assets and other assets	-13,400,000	1,010,000	-10,158,000	-9,502,000	-513,000	1,123,000	6,336,000	3,290,000	-11,708,000	2,738,000	29,160,000	44,262,000	85,367,000	-115,324,000	-4,423,000	5,512,000	-3,505,000	-24,590,000	602,000	15,674,000	8,866,000	35,155,000	-26,383,000	-2,386,000	12,642,000	5,957,000	22,657,000	9,395,000
related party receivables	-56,000	817,000	278,000	-1,106,000	-2,000	965,000	145,000	-66,000	-562,000	-119,000	470,000	1,163,000	-358,000	-163,000	4,000	110,000	-182,000	7,082,000	301,000	-458,000	237,000	557,000	76,000	366,000	319,000	-1,310,000	-314,000	100,000
accounts payable, accrued expenses and other liabilities	-124,578,000	18,577,000	69,748,000	45,622,000	-112,626,000	66,256,000	46,853,000	59,852,000	62,174,000	42,723,000	-150,483,000	-55,869,000	-108,510,000	322,724,000	-48,777,000	-11,113,000	-11,682,000	16,089,000	-37,226,000	-21,430,000	6,565,000	-19,667,000	34,839,000	3,675,000	-394,000	-14,233,000	695,000	-28,354,000
related party payables	-41,102,000	-2,176,000	-2,186,000	6,417,000	-1,124,000	34,102,000	10,720,000	4,124,000	5,495,000	1,241,000	1,672,000	-407,000	-5,029,000	2,376,000	5,132,000	1,632,000	-75,000	-7,172,000	3,260,000	45,000	1,740,000	-3,834,000	3,695,000	5,203,000	-2,200,000	1,569,000	656,000	12,000
net cash from operating activities	-26,743,000	130,315,000	118,450,000	83,819,000	7,408,000	118,078,000	141,774,000	39,657,000	-4,410,000	-11,345,000	139,712,000	-23,292,000	93,570,000	-125,521,000	120,343,000	63,261,000	82,364,000	-51,933,000	148,128,000	105,958,000	44,776,000	179,241,000	49,026,000	-50,889,000	139,910,000	21,094,000	-108,410,000	259,651,000	62,129,000
capital expenditures	-8,175,000	-21,773,000	-12,298,000	-22,830,000	-13,162,000	-15,155,000	-16,945,000	-10,626,000	-9,198,000	-12,003,000	-9,688,000	-11,466,000	-19,099,000	-5,049,000	-10,793,000	-17,498,000	-10,645,000	-7,809,000	-11,776,000	-29,533,000	-10,993,000	-8,552,000	-7,367,000	-4,517,000	-13,035,000	-11,641,000	-17,988,000	-20,023,000	-26,465,000
free cash flows	-34,918,000	108,542,000	106,152,000	60,989,000	-5,754,000	102,923,000	124,829,000	29,031,000	-13,608,000	-23,348,000	130,024,000	-34,758,000	74,471,000	-130,570,000	109,550,000	45,763,000	71,719,000	-59,742,000	136,352,000	76,425,000	33,783,000	170,689,000	41,659,000	-55,406,000	126,875,000	9,453,000	-126,398,000	239,628,000	35,664,000
cash flows from investing activities:
purchases of property, plant and equipment	-8,175,000	-21,773,000	-12,298,000	-22,830,000	-13,162,000	-15,155,000	-16,945,000	-10,626,000	-9,198,000	-12,003,000	-9,688,000	-11,466,000	-19,099,000	-5,049,000	-10,793,000	-17,498,000	-10,645,000	-7,809,000	-11,776,000	-29,533,000	-10,993,000	-8,552,000	-7,367,000	-4,517,000	-13,035,000	-11,641,000	-17,988,000	-20,023,000	-26,465,000
acquisition of intangible assets	-7,850,000	-3,000,000	-7,414,000	-900,000	-4,200,000	-600,000	-3,600,000	-750,000	-9,700,000	-1,150,000	-338,000	0	-31,800,000				0			-1,100,000	-2,200,000	0	-1,050,000
deposits for future acquisition of property, plant and equipment	-5,685,000		-2,752,000	-3,672,000	-960,000		-167,000	-78,000	-862,000
proceeds from sale of property, plant and equipment			0	855,000	524,000
net cash from investing activities	-21,710,000	-45,454,000	-22,464,000	-26,547,000	-17,798,000	-16,059,000	-20,712,000	-6,465,000	-19,760,000	-12,284,000	-11,737,000	-11,466,000	-49,332,000	-16,116,000	-97,395,000	-86,969,000	-11,633,000	-82,887,000	-12,693,000	-31,795,000	-14,782,000	-8,927,000	-262,042,000	-4,767,000	29,982,000	-23,329,000	-21,466,000	5,321,000	-40,775,000
cash flows from financing activities:
payments of principal on debt, revolving credit facilities, financing leases and other	-140,842,000		-2,554,308,000	-15,548,000	-235,528,000		-54,506,000	-15,500,000	-63,377,000
proceeds from issuance of debt	134,673,000	0																		0	0	0	180,000,000					0	0
payments of deferred financing and refinancing costs	-1,982,000		-73,228,000									0	-41,000
borrowings on revolving credit facilities			0	0	218,000,000		0	0	48,000,000
proceeds from exercise of stock options	38,000	553,000	653,000	685,000	69,000	151,000	617,000	358,000	28,000			0	423,000	128,000	111,000	19,000	153,000	5,000	676,000	105,000	58,000	153,000	5,000	15,000	0	375,000	1,010,000	635,000
employee payroll tax withholding on restricted stock unit vesting	-44,305,000					-387,000	-194,000	-159,000	-7,212,000	-11,000	-2,022,000	-88,000	-192,000	-290,000	-3,001,000	-69,000	-217,000	-276,000	-2,102,000	-68,000	-238,000	-54,000	-503,000	0	-5,000
tax and other distributions to non-controlling interests	-7,147,000	-5,023,000	-13,867,000
proceeds from alliance party	510,000	795,000
net cash from financing activities	-59,055,000	-10,120,000	59,443,000	-41,687,000	-39,166,000	-61,204,000	-92,346,000	-35,086,000	-23,155,000	-12,256,000	-12,900,000	-22,167,000	-46,132,000	23,249,000	-61,570,000	-30,350,000	-43,555,000	-38,068,000	-26,149,000	-11,282,000	-14,808,000	-310,082,000	467,979,000	-7,298,000	-7,596,000	-9,075,000	-21,864,000	-218,920,000	82,600,000
effect of foreign exchange rate on cash	-1,023,000	-209,000	-694,000	-307,000	-470,000	-740,000	7,000	-101,000	-165,000	-602,000	767,000	-3,739,000	-397,000	25,000	-1,572,000	178,000	290,000	227,000	-593,000	590,000	192,000	1,115,000	-860,000	-1,282,000	-2,260,000	1,589,000	-296,000	534,000	-351,000
net decrease in cash, cash equivalents, and restricted cash	-108,531,000			15,278,000	-50,026,000								-2,291,000													-9,721,000	-152,036,000
cash, cash equivalents, and restricted cash - beginning of period	312,939,000	0	0	0	118,420,000	0	0	0	99,107,000	0	35,227,000	0	0	0	256,739,000	0	0	0	347,121,000	0	0	0	152,822,000	0	0	0	218,779,000	0	0
cash, cash equivalents, and restricted cash - end of period	204,408,000	74,532,000	154,735,000	15,278,000	68,394,000	40,075,000	28,723,000	-1,995,000	51,617,000	-36,487,000	151,069,000	-60,664,000	-2,291,000	-118,363,000	216,545,000	-53,880,000	27,466,000	-172,661,000	455,814,000	63,471,000	15,378,000	-138,653,000	406,925,000	-64,236,000	160,036,000	-9,721,000	66,743,000	46,586,000	103,603,000
cash and cash equivalents - end of period	197,656,000	80,780,000	129,705,000	12,357,000	59,187,000	36,546,000	30,237,000	-2,751,000	46,520,000	-35,390,000	144,674,000	-61,359,000	-4,644,000	-118,498,000	210,477,000	-54,865,000	24,349,000	-173,791,000	452,097,000	60,100,000	15,135,000	-139,095,000	405,238,000	-61,541,000	157,845,000	-9,053,000	63,946,000	48,202,000	103,671,000
restricted cash - end of period	4,174,000	-5,885,000	25,085,000	3,059,000	6,583,000	3,529,000	-1,514,000	756,000	5,097,000	-1,097,000	6,395,000	695,000	2,353,000	135,000	6,068,000	985,000	3,117,000	1,130,000	3,717,000	3,371,000	243,000	442,000	1,687,000	-2,695,000	2,191,000	-668,000	2,797,000	-1,616,000	-68,000
long-term restricted cash included in other assets - end of period	2,578,000	-363,000	-55,000	-138,000	2,624,000
intangible asset impairment charges		0				0	0	0	920,000			18,295,000	674,000			22,004,000	688,000			1,720,000	32,364,000	759,000	2,416,000	14,171,000	79,514,000	3,012,000	76,084,000	39,454,000
change in fair value of contingent consideration						0	-1,030,000	0	100,000	-6,364,000	2,457,000	2,226,000	-1,425,000	-270,000	200,000	-100,000
deposits for future acquisition of property, plant, and equipment											-1,711,000	0	1,567,000	-2,067,000	-1,888,000	-556,000	-988,000	-750,000	-917,000	-1,162,000
proceeds from sale of property, plant, equipment and other
proceeds from sale of subsidiary						7,005,000	0
payments of principal on debt, revolving credit facility, financing leases and other											-72,659,000	-17,654,000
payments of deferred financing, refinancing costs and debt extinguishment costs
borrowings on revolving credit facility											80,000,000	0	0
employee payroll tax withholding on restricted stock unit and performance stock unit vesting		-321,000	-129,000	-189,000	-21,639,000
payment of principal on notes payable - related party							-32,704,000
net increase in cash, cash equivalents, and restricted cash		74,532,000				40,075,000	28,723,000	-1,995,000	-47,490,000	-36,487,000	115,842,000				-40,194,000	-53,880,000	27,466,000	-172,661,000	108,693,000	63,471,000	15,378,000	-138,653,000	254,103,000	-64,236,000				46,586,000	103,603,000
unrealized foreign currency gain
unrealized foreign currency (gain) loss
tax distributions to non-controlling interests					-68,000		-5,559,000	-8,289,000	-594,000	-17,338,000	-18,219,000		-3,214,000	-6,753,000	-3,164,000		-9,127,000				-3,201,000
net loss									-81,678,000		-10,094,000														-363,392,000
adjustments to reconcile net loss to net cash from operating activities:
insurance recoveries for property and equipment losses												0	0
acquisitions of business
proceeds from insurance recoveries for property and equipment losses												0	0
payments of deferred consideration for acquisitions - related party												0	-500,000	0	-43,998,000
acquisition of redeemable non-controlling interests
tax distributions to non-controlling interest
repayment of related party note																	0	0	-1,000,000										0
non-cash property losses
acquisitions of businesses, net of cash acquired												0	0
payments of principal on financing lease - related party																0	0	0	-93,000	-277,000	-272,000	-267,000	-263,000	-563,000	-841,000	-247,000	-619,000
loss on refinancing - revolving credit facility
saol acquisition
acquisition of redeemable non-controlling interest													0	0	-1,722,000													0
acquisition of business															-84,714,000
gain on sale of international businesses																					0
non-cash restructuring and asset-related (benefit) charges
distribution of earnings to and acquisition of non-controlling interest
payments of principal on debt, financing leases and other														-53,214,000	-9,796,000	-9,846,000	-34,364,000	-10,246,000	-23,630,000	-9,433,000	-9,428,000
supplemental disclosure of cash flow information:
cash paid for interest															27,289,000	30,069,000	30,237,000	31,524,000	29,917,000	30,979,000	30,774,000	33,047,000	35,386,000	36,696,000	40,769,000	41,071,000	40,032,000	42,430,000	38,684,000
cash paid for income taxes															4,387,000			3,877,000	733,000
supplemental disclosure of non-cash investing and financing activity:
contingent consideration for acquisition															8,796,000
gain from reduction of tax receivable agreement liability																								0
amortization of levothyroxine transition agreement asset																								0	0	0	36,393,000
amortization of debt issuance costs																								1,629,000	1,631,000	1,617,000	1,601,000	1,639,000	1,643,000
deferred tax provision																								33,000				-328,000	5,882,000
non-cash property and equipment losses
acquisition of product rights and licenses																								-250,000	0			0	-11,000,000
acquisitions, net of cash acquired																-72,715,000	0			0	2,640,000	-375,000	-253,625,000					0	-3,310,000
proceeds from sale of international businesses, net of cash sold																								0	0
payments of deferred financing costs and debt extinguishment costs																												0	0
tax distribution to non-controlling interest																								0	0	0	-13,494,000	-71,086,000
repayment of related party notes
cash received for income taxes																-3,975,000				-9,303,000	113,962,000	-1,088,000	-3,430,000		3,324,000	-1,180,000	9,713,000
notes payable for acquisitions - related party																				0	0	0	36,033,000
deferred consideration for acquisition - related party																0	0
contingent consideration for acquisition - related party																-400,000	0
payable for acquisition of product rights and licenses																-1,200,000											50,000,000
asset-related credit
payments of deferred financing costs																					0	0	-4,102,000
distribution of earnings to and acquisition of non-controlling interests
payments for restricted stock unit tax vesting
income taxes receivable associated with the cares act																						0	-110,069,000
tax distribution to non-controlling interests																			9,757,000
net borrowings on revolving credit facility																							300,000,000
loss on extinguishment of debt																												0
loss on sale of international businesses																								-328,000
non-cash restructuring and asset-related charges																								536,000	10,609,000
stock-based compensation and ppu expense																								5,013,000	6,095,000			3,606,000	3,590,000
proceeds from surrender of corporate owned life insurance																								0
proceeds from sales of property, plant and equipment
net payments on revolving credit line
payments of principal on financing obligation - related party
equity contributions																												0	0
capital contribution from non-controlling interest																													0
distributions to members																												0	0
acquisition of non-controlling interest																								0	0	-1,532,000	-2,011,000
distribution to members																												0	0
non-cash restructuring and asset-related (credit) charges
deferred tax benefit																										-8,325,000	-9,884,000
gain on sale of international business																											-8,818,000
cash sold with international business																											-3,478,000
payments of principal on debt and financing leases																							-7,158,000
receivable from the sale of international business																											35,837,000
payments of principal on debt and capital leases																								-6,750,000	-6,750,000	-6,750,000	-6,750,000
net (payments) borrowings on revolving credit line
capital contribution from (dividend to) non-controlling interest
cash received, net for income taxes
receivable from the sale of international businesses
note payable resulting from the ireland building purchase
transaction costs paid by amneal holdings
net borrowings on revolving credit line
gain on termination of lease
payments on revolving credit line
payments of financing obligation - related party
stock-based compensation expense																											4,347,000
loss on sale of certain international businesses																												146,000
proceeds from sale of certain international businesses, net of cash sold
receivable from the sale of certain international businesses
transaction costs paid by amneal holdings, llc
investing activities:
financing activities:
payments of principal on debt, financing obligations and capital leases
income taxes paid
loss on extinguishment and modification of debt
gain termination of lease
allowance for doubtful accounts provision
other
prepaid expenses and other current assets
related-party receivables
other assets
accounts payable and accrued expenses
other liabilities
related-party payables
payments on capital leases
payments on financing obligations
payments on debt
exercise of stock options
other current assets and current liabilities
net change in cash and cash equivalents
cash and cash equivalents at the beginning of period
cash and cash equivalents at the end of year

Amneal Pharmaceuticals, Inc(NYSE:AMRX)

Amneal Pharmaceuticals, Inc
(NYSE:AMRX)